The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.

For both treatment groups, sTK1 increased significantly from baseline to visit 2 in both pCR and non-pCR cases, we also observed a marginally significant change of sTK1 from visit 2 to visit 3 in non-pCR cases but not in pCR cases.

also in 26,082 other papers